DEA Drug Take Back Day Breaks Collection Record
BIOtech Now George Goodno Last week, the Drug Enforcement Administration’s 14th Prescription Drug Take Back Day collected a record-setting 456 tons of potentially […]
Author: Paul
Biotech Faces Up to Our Own Leadership Diversity Challenge
BIOtech Now Jim Greenwood Disease is an equal-opportunity enemy. It strikes men and women; children and seniors; and people of every race, […]
A New Approach to Assessing Value in Health Care
BIOtech Now Dan Durham It’s an important and exciting time in the biotech industry. Spending on prescription drugs has proven to be […]
The Risky Business of Drug Importation
BIOtech Now Andrew Segerman You hear it all the time: prescription drugs in the United States are too expensive, so let’s go […]
Jim Greenwood Talks Biotech Innovation With Bloomberg Radio
BIOtech Now George Goodno While in Boston this week, BIO CEO Jim Greenwood sat down with Bloomberg Boston Bureau Chief Tom Moroney […]
A New Link to an Old Disorder
BioTechniques News Scientists find a novel mutation causing a rare blood disorder that makes people photosensitive and anemic. Full BioTechniques Article here […]
A Trick to Escape Becoming a Treat
BioTechniques News Researchers have Identified the genes involved in the sea cucumber’s gory ritual of expelling and regenerating its gut. Will it […]
Fright Night: When Movies Control the Brain
BioTechniques News Hitchcock and Kubrick grip us in scenes and sounds of horror. How do these movies affect our brains? Full BioTechniques […]
Biomedical Innovation Can Help Solve the Opioid Crisis
BIOtech Now Andrew Segerman Opioid abuse in America touches the lives of millions. It’s estimated that more than 1,000 men and women […]
A Flawed Bill That Would Harm Seniors
BIOtech Now Brian Newell The Medicare prescription drug program has been a remarkable success for both seniors and taxpayers, providing affordable medicines […]
ICYMI: A Bipartisan Drug Cartel?
BIOtech Now Daniel Seaton “As false as it is implausible.” That’s how a Wall Street Journal editorial describes a recent story by […]
FDA’s Historic Gene Therapy Approvals Could Be Beginning of the End of Blood Cancer
BIOtech Now Jim Greenwood In his inaugural address this June as chairman of the world’s largest biotechnology industry group, CEO John Maraganore […]
New Infographic: The Bayh-Dole Act
BIOtech Now Brian Newell $1.3 trillion in economic output. Support for roughly 4.2 million jobs. The creation of more than 11,000 start-up […]
ICYMI: Jim Greenwood Weighs In on the Future of Drug Pricing
BIOtech Now Andrew Segerman Rewarding for quality – not quantity – is becoming more and more common in health care. Providers are […]
ICYMI: Drug Development is Complicated. Let’s Start with the Facts.
BIOtech Now Andrew Segerman Here’s a fact you might not have known: 90% of drug development programs fail. Yet a recent paper […]
Challenges and Opportunities in Personalized Medicine
BIOtech Now Jeremy Isenberg Last week the sixth annual Patient and Health Advocacy Summit brought hundreds of patient advocates, industry experts and […]
FDA’s Dr. Theresa Mullin Addresses BIO Patient and Health Advocacy Summit
BIOtech Now Paige Decker “So, Theresa, where did you grow up? Did you have any siblings?” asked Marc Boutin, CEO of the […]
Welcome to the 2017 BIO Patient and Health Advocacy Summit!
BIOtech Now Theresa Brady Patients are at the forefront of everything we do. Each year BIO brings the patient stakeholder community together […]
Oncology Innovation Has Produced Major Drop in Pediatric Cancer Deaths
BIOtech Now Jim Greenwood One of the toughest parts of working in the biotechnology industry is the likelihood that you will eventually […]
ICYMI: Citizens Against Government Waste Speaks Out Against Waste in 340B Drug Discount Program
BIOtech Now Daniel Seaton Writing this week for The Hill, Elizabeth Wright of Citizens Against Government Waste highlights an egregious example of […]